Skip to main content
Kexing Biopharm logo

Kexing Biopharm — Investor Relations & Filings

Ticker · 688136 ISIN · CNE100006ZG6 LEI · 529900Z34Q1M9A907771 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 752 across all filing types
Latest filing 2025-03-18 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 688136

About Kexing Biopharm

https://www.kexingbiopharm.com/

Kexing Biopharm is an innovative biopharmaceutical enterprise engaged in the research, development, production, and sales of recombinant protein drugs and micro-ecological preparations. The company focuses on developing treatments for therapeutic areas including kidney diseases, oncology, antiviral therapy, autoimmune disorders, metabolic diseases, and degenerative diseases. A key product in its portfolio is Erythropoietin Injection. Kexing Biopharm maintains a comprehensive quality system that aligns with international standards, covering the entire drug lifecycle from production and quality control to release and transportation, ensuring the continuous and stable manufacturing of safe and effective medicines.

Recent filings

Filing Released Lang Actions
关于公司实际控制人兼董事长提议回购公司股份的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from the company's board regarding a proposal by the actual controller and chairman to repurchase company shares. It details the proposal's background, purpose, specifics of the share repurchase plan, funding, and timeline. There is no financial report, earnings data, or regulatory certification. The content focuses on the company's capital structure change through share repurchase. Therefore, this fits the category of a Capital/Financing Update (CAP). The document length is short and it is not merely announcing a report publication, so it is not RPA or RNS.
2025-03-18 Chinese
2024年度业绩快报公告
Earnings Release Classification · 95% confidence The document is titled as a "2024年度业绩快报公告" which translates to "2024 Annual Performance Express Announcement" or "Earnings Summary Announcement." It contains preliminary financial data for the year 2024, including revenue, profit, and other key financial metrics. The data is explicitly stated as preliminary and unaudited, with a note that the final audited data will be in the 2024 Annual Report. The document is relatively short (1660 characters) and serves as an initial earnings release or summary rather than a full annual report. It does not contain full financial statements or detailed analysis, but rather key highlights and a brief explanation of performance and risks. This matches the definition of an Earnings Release (ER), which is an initial announcement of quarterly or periodical financial results with key highlights only. FY 2024
2025-02-27 Chinese
自愿披露关于人干扰素α1b吸入溶液获得美国FDA新药临床试验许可的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the approval by the US FDA for clinical trials of a new drug (human interferon α1b inhalation solution). It details the drug, the approval, and the impact on the company. The document is short (1440 characters) and serves as a regulatory announcement about a clinical trial approval, not a financial report or detailed presentation. It does not contain financial statements or detailed financial data. It is not an earnings release, annual report, or management report. It is a regulatory announcement about a significant event related to the company's drug development. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2025-02-05 Chinese
2024年年度业绩预告
Earnings Release Classification · 95% confidence The document is titled '2024 年年度业绩预告' which translates to '2024 Annual Performance Forecast'. It provides preliminary profit estimates for the full fiscal year 2024, including net profit attributable to the parent company and adjusted net profit excluding non-recurring items. It explicitly states that the forecast is unaudited and based on preliminary calculations by the financial department. The document also includes a risk warning about the forecast's uncertainty and notes that the final audited annual report will be published later. The document length is 1263 characters, which is relatively short and primarily serves as a performance forecast announcement rather than a full annual report containing detailed financial statements and analysis. Therefore, this document is best classified as an Earnings Release (ER), which covers initial announcement of periodical financial results or forecasts with key highlights only. FY 2024
2025-01-17 Chinese
舆情管理制度
Governance Information Classification · 95% confidence The document is titled '舆情管理制度' which translates to 'Public Opinion Management System' and outlines the company's internal policies and procedures for managing public opinion and media crises. It includes organizational structure, responsibilities, principles, reporting processes, and confidentiality obligations related to public opinion management. There is no financial data, no mention of financial results, no shareholder meeting materials, no voting results, no legal proceedings, no capital changes, no audit information, and no regulatory filings in the form of certifications or announcements. The document is a governance-related internal policy document issued by the company's board, effective from a specific date. Therefore, it fits best under Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices.
2024-12-27 Chinese
关于核心技术人员调整暨新增认定核心技术人员的公告
Board/Management Information Classification · 95% confidence The document is an announcement from a company about adjustments to its core technical personnel, including the removal of one individual from the core technical staff and the addition of two new core technical personnel. It details their backgrounds, roles, and the impact of these changes on the company's intellectual property and operations. There is no financial data, no mention of financial results, no regulatory filings or certifications, and no reference to shareholder votes or meetings. The document is a corporate announcement about management and personnel changes specifically related to core technical staff, which fits best under Board/Management Information (MANG). The document length is 2765 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, the classification is MANG with high confidence.
2024-12-27 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.